She further demanded taxpayers give money to the abortion cartel's leading player, Planned Parenthood, for the destruction of the unborn.

She insisted on the necessity of "reproductive health care."

It seems Sherrill also is out of touch with Supreme Court precedent.

The problem had been highlighted by a fight for religious freedom conducted by Waco Justice of the Peace Dianne Hensley. She declined to perform same-sex weddings, instead referring people to another authority within walking distance, and who would perform the event in the same time frame and at the same price as Hensley.

The state Commission on Judicial Conduct has accused her of violating the rules, and she sued, explaining there were a number of constitutional and legal protections for her to live by her Christian faith.

The commission had claimed her adherence to her faith showed a "bias" against some Texans.

The bank has been trying to fulfill its mandates of stable prices, in the range of a 2% inflation, while promoting maximum employment.

The Federal Open Market Committee said in its statement risks remain on both agendas.

One member of the board favored a half-percentage cut..

LisbofTikTok is calling Pritzker a "disgusting liar," posting a video montage of the governor comparing Trump to Nazis.

It was only last week at the Economic Club of Chicago that Pritzker linked Trump's actions with ICE and Border Patrol agents to Nazi attacks against Jews in 1930s Germany.

"This is how authoritarian regimes do it," Pritzker said.

Deranged Jasmine Crockett goes on an unhinged rant calling President Trump “Temu Hitler.” This is the kind of rhetoric that led to two assassination attempts against President Trump.

Former University of Colorado player, now Trail Blazers coach Chauncey Billups, and Miami Heat guard Terry Rozier were among those arrested.

"Rozier is accused of participating in an illegal sports betting scheme using private insider NBA information. Billups is charged in a separate indictment alleging a wide-ranging scheme to rig underground poker games that were backed by Mafia families," the report said.

Smith took to a broadcast outlet to complain, and accused Trump, charging the situation "was fueled by Trump and his thirst for revenge," the report said.

"Fifteen years ago, the U.S. Food and Drug Administration recognized India's strategic importance to the U.S. – and to the agency in fulfilling our mission – and opened one of the FDA's first foreign offices in India. Since that time, the Indian medical products sector has continued to grow as has our reliance on medical products made in India.. India sometimes describes itself as the 'pharmacy to the world.'" – Robert M. Califf, M.D., Commissioner of Food and Drugs during the Biden administration

For years, India has branded itself as the "pharmacy of the world," a title repeated by politicians, trade lobbyists and global institutions. The narrative paints India as a benevolent supplier of affordable medicine to developing nations and a trusted producer of lifesaving generics for the West. But behind that reputation lies a far darker reality, one built not on innovation or quality, but on cost-cutting, corruption and corner-cutting.

India's rise in pharmaceuticals was not driven by breakthroughs in science or superior manufacturing. It began when India rewrote its patent laws in the 1970s, allowing domestic firms to reverse-engineer Western drugs without licensing fees. That loophole fueled an explosion of generic production: cheap, fast and profitable. When international patent protections were later restored in the U.S. 2005, Indian manufacturers pivoted again, flooding foreign markets with off-patent generics while undercutting competitors through low labor costs, weak oversight and questionable testing practices.

Two countries, China and India, dominate the American drug supply. Together they account for 70 to 80 percent of the generics and key ingredients in U.S. medicine cabinets. India alone produces nearly half of all finished generics sold in this country, while China supplies many of the raw compounds used to make them. This dependency doesn't just threaten America's health; it hands foreign governments and corporations enormous leverage over U.S. national security.

The cost of cutting corners: Fraud, deaths and denial

The scale of dependence would be less alarming if quality were assured. In February, when researchers revealed that Indian-made generic drugs carried a significantly higher risk of serious side effects – including hospitalization, disability and death – than their U.S.-manufactured equivalents, the industry's first reaction was denial.

India's pharmaceutical lobby immediately challenged the findings. Industry representatives accused the researchers of "bias," arguing the analysis unfairly targeted India's global role while insisting its products met "international quality standards." Yet, while the industry defended its image, the actual evidence at home and abroad told a much darker story.

Top pharma alliance refutes 'ill-researched' US study linking Indian generics to higher adverse events

Fact: Over recent years, Indian-made cough syrups have been linked to hundreds of children's deaths across multiple continents. The World Health Organization has documented more than 300 child fatalities caused by syrups laced with diethylene glycol (DEG) and ethylene glycol (EG), industrial toxins used in antifreeze.

Between 2022 and 2023, fatal outbreaks were reported in The Gambia, Uzbekistan and Indonesia. In 2025, new deaths in the large Indian state Madhya Pradesh were traced to syrups containing nearly 500 times the allowable diethylene glycol limit.

Each time, regulators and manufacturers called the tragedies "isolated incidents." But repetition reveals a pattern: Rather than acknowledge systemic failure, authorities compartmentalized the crisis, treating each cluster of deaths as unrelated. The strategy kept headlines small, tempered international outrage and allowed exports to continue uninterrupted.

The pattern looks less like bureaucratic incompetence and more like strategic containment, a deliberate effort to protect India's global image as the "pharmacy of the world."

As India's Biden-era Health Minister Dr. Mansukh Mandaviya declared, "The Indian pharma industry should strive to maintain the reputation of India as the 'Pharmacy of the World' … Indian pharma industry never compromises with the quality of the medicines."

Yet data from India's own regulators contradict that claim. Over 36% of Indian drug-manufacturing plants inspected since mid-2023 were ordered to shut due to non-compliance.Despite this, the government continues to celebrate export growth while quietly ignoring the negligence and corruption within the pharmaceutical sector documented by international agencies. The same companies implicated in earlier poisonings remain operational, exporting to dozens of countries under the banner of "affordable medicine."

This reveals the true nature of India's pharmaceutical problem: not a lack of awareness, but a lack of accountability. When lives are lost, the response is rarely reform – rather, it's public relations. At best, the government's actions remain reactive: bans, recalls and arrests occur only after fatalities make global news. As Udaya Bhaskar of the All India Drugs Control Officers bluntly admitted,
"It's not the government's job to test every batch. That responsibility lies with the manufacturer."

In 2024, India's top regulator declared the crisis "under control." Yet within months, that assurance unraveled as new child deaths emerged and the owner of Sresan Pharmaceuticals was arrested and the World Health Organization issued a fresh global alert warning that contaminated syrups from multiple Indian companies posed a "serious risk to public health."

Yet India's response cycle of deny, deflect and delay continued.

The FDA's complicity and India's embedded influence

A June 2025 ProPublica investigation, "Threat in Your Medicine Cabinet: The FDA's Gamble on America's Drugs," shows how the Food and Drug Administration repeatedly allowed overseas factories, largely in India, to ship products even after serious manufacturing and quality failures.

More than 20 plants under U.S. import bans for contamination, falsified records and filthy labs received exemptions that let at least 150 drugs or ingredients to keep flowing into the American market: One from China, one from Hungary – and 148 from India.

Inspectors found metal shavings on production lines, raw materials contaminated with "extraneous matter" and "blackish" vials of injectable medication that still reached U.S. pharmacies. Yet the FDA, pressured by industry lobbyists and afraid of drug shortages, looked the other way. Instead of sounding the alarm, it kept the public and even Congress in the dark.

Adverse-event reports linked to these drugs included hospitalizations and deaths, but the agency rarely investigated.

What makes the crisis even more dangerous is the degree to which Indian pharmaceutical multinationals have embedded themselves inside America. They operate embedded U.S. subsidiaries with sales headquarters, policy offices and manufacturing plants that give them a foothold in America's regulatory ecosystem. Among the most prominent are Dr. Reddy's, Sun Pharma (including legacy Ranbaxy and Ohm), Lupin, Zydus, Aurobindo (through Aurolife and Aurobindo USA), Intas (via Accord Healthcare), Cipla and Glenmark. Most anchor their operations in New Jersey, Maryland and North Carolina.

These firms exert influence through direct federal lobbying and powerful trade groups such as the Association for Accessible Medicines (AAM), the U.S.-India Business Council (USIBC) and the U.S. India Strategic Partnership Forum (USISPF).

Shockingly, 13 of 23 board seats – more than half of the Association for Accessible Medicines leadership – are held by executives of companies owned or controlled by Indian parent corporations. These same Indian firms supply roughly 40-50% of the U.S. generic drug market, meaning they have direct influence over both production and policy advocacy in Washington through the AAM.

The overlap illustrates a significant conflict of interest: Companies repeatedly cited for safety violations, contamination and FDA noncompliance abroad are also shaping the U.S. generic drug policy agenda domestically.

This network grants them oversized market power, since American regulators and hospitals rely on their products, yet they also help shape the very rules meant to govern them. As a result, when quality or life-and-death safety concerns threaten profits, enforcement is easily softened and accountability delayed.

The ProPublica investigation exposes a dangerous cycle: The FDA, pressured to avoid shortages and influenced by industry ties, grants waivers to repeat violators; corporations, backed by Washington lobbyists, continue shipping questionable products – and American patients bear all the risk. The oversight process, once designed to protect public health, has become entangled in the same global networks that profit from America's dependency. Each "exemption" and import waiver further entrenches a system wherein profit outweighs safety, dependency overrides accountability and foreign influence seeps into the very heart of U.S. health policy.

U.S. dangerously reliant on high-risk imported drug supply

The human cost of outsourcing health

Consider these real-life nightmares: A young mother loses her life after receiving a contaminated IV infusion manufactured in India. Patients lose their eyesight after using Indian-made eyedrops. A five-year-old child dies of kidney failure after taking cough syrup laced with industrial toxins. Heart patients discover their medication has been recalled because of impurities introduced through contamination during production. Parents opening their children's antibiotic find worms floating inside.

In these and other documented horror stories tied to Indian pharmaceutical exports over the past several years, each case underscores the same truth: When safety takes a back seat to profit, people die. The promise of affordable medicine becomes meaningless when the cost is measured in human lives.

Rebuilding domestic pharmaceutical production isn't just sound and necessary economic policy; it's national security. Closing the $118.3 billion pharmaceutical trade deficit would not only create jobs, it would restore accountability to an industry that should never have been outsourced in the first place.

Indian drugmakers can retain U.S. dominance even with tariffs, says industry body

If America is serious about protecting its citizens' health, it must reclaim control of its own medicine supply. In the era of MAHA – "Make America Healthy Again" – perhaps the first step is ending dependence on foreign manufacturers whose repeated failures are making many people sicker – not better.

The publication said the report was from a source who was invited to the events.

The comment came at the Army's UAS and Launched Effects Summit at Fort Rucker in Augus, where the contractor also provided a look at a new and unorthodox project.

The Post it was given access to a video in which a "20-foot across four-winged flier zooms through the skies just above the tree-line."

Observers said, in the Post, "It feels like it's a UFO because it defies what you're expecting to see."

The Post noted, "All conference attendees were approved by brass at Fort Rucker, which enacted strict rules for participation, including the exclusion of any drone or craft containing any Chinese-made parts, the source revealed."

The report noted the rash of supposed drone sightings over New Jersey started Nov. 13, 2024, near an Army base, then continued across the state into December.

Officials earlier attributed the sightings to hobbyists, recreational pilots and others.

WND had reported at the time the White House said the flights were authorized but provided few other details.

It did reassure Americans, "This was not the enemy."